Skip to main content

Table 4 Associations of DNA methylation aging markers with CRC-specific mortality

From: Whole blood DNA methylation aging markers predict colorectal cancer survival: a prospective cohort study

Markers

Categories

All stages

Stage I and II

Stage III

Stage IV

P for interaction

ndeath/ncases

HR (95% CI)*

ndeath/ncases

HR (95% CI)#

ndeath/ncases

HR (95% CI)#

ndeath/ncases

HR (95% CI)#

AgeAccelHorvath

Tertile 1

203/732

1.00 (Ref.)

34/362

1.00 (Ref.)

75/257

1.00 (Ref.)

93/105

1.00 (ref.)

Tertile 2

184/731

1.03 (0.83, 1.28)

32/401

0.88 (0.54, 1.45)

69/234

1.02 (0.73, 1.42)

82/91

1.11 (0.80, 1.52)

Tertile 3

209/728

1.17 (0.94, 1.46)

49/390

1.67 (1.06, 2.65)

67/230

1.17 (0.83, 1.66)

92/109

0.95 (0.68, 1.31)

Per SD increase

596/2191

1.04 (0.95, 1.13)

115/1153

1.17 (0.97, 1.41)

211/721

1.07 (0.93, 1.24)

267/305

0.94 (0.81, 1.08)

0.256

AgeAccelHannum

Tertile 1

173/732

1.00 (Ref.)

28/384

1.00 (Ref.)

77/266

1.00 (Ref.)

68/78

1.00 (ref.)

Tertile 2

204/731

0.93 (0.73, 1.17)

45/386

1.46 (0.89, 2.40)

61/234

0.82 (0.57, 1.18)

98/110

0.88 (0.60, 1.29)

Tertile 3

219/728

1.06 (0.83, 1.36)

42/383

1.24 (0.72, 2.12)

73/221

1.13 (0.78, 1.65)

101/117

0.90 (0.60, 1.35)

Per SD increase

596/2191

1.07 (0.97, 1.19)

115/1153

1.05 (0.84, 1.31)

211/721

1.10 (0.94, 1.29)

267/305

1.02 (0.87, 1.20)

0.258

DNAmMRscore

Tertile 1

166/733

1.00 (Ref.)

31/409

1.00 (Ref.)

63/241

1.00 (Ref.)

72/83

1.00 (ref.)

 

Tertile 2

176/729

0.90 (0.68, 1.17)

38/395

1.07 (0.61, 1.86)

53/229

0.81 (0.53, 1.25)

84/101

0.82 (0.56, 1.21)

 

Tertile 3

254/729

1.54 (1.11, 2.15)

46/349

1.38 (0.71, 2.66)

95/251

1.61 (1.00, 2.57)

111/121

1.21 (0.77, 1.88)

Per SD increase

596/2191

1.30 (1.11, 1.53)

115/1153

1.34 (0.99, 1.81)

211/721

1.36 (1.10, 1.67)

267/305

1.06 (0.86, 1.29)

0.041

AgeAccelPheno

Tertile 1

168/732

1.00 (Ref.)

30/389

1.00 (Ref.)

72/262

1.00 (Ref.)

65/78

1.00 (ref.)

Tertile 2

196/731

1.20 (0.96, 1.51)

40/394

1.08 (0.66, 1.78)

63/231

1.01 (0.70, 1.45)

93/101

1.51 (1.06, 2.14)

Tertile 3

232/728

1.25 (0.98, 1.59)

45/370

1.38 (0.84, 2.29)

76/228

1.26 (0.89, 1.79)

109/126

1.26 (0.88, 1.81)

Per SD increase

596/2191

1.15 (1.04, 1.27)

115/1153

1.18 (0.97, 1.42)

211/721

1.22 (1.06, 1.42)

267/305

1.08 (0.92, 1.25)

0.281

AgeAccelGrim

Tertile 1

175/732

1.00 (Ref.)

32/404

1.00 (Ref.)

80/257

1.00 (Ref.)

63/70

1.00 (ref.)

Tertile 2

188/731

0.92 (0.73, 1.17)

38/379

1.14 (0.68, 1.93)

60/245

0.79 (0.54, 1.15)

90/103

0.92 (0.64, 1.34)

Tertile 3

233/728

1.28 (0.84, 1.93)

45/370

1.53 (0.85, 2.73)

71/219

1.19 (0.80, 1.77)

114/132

0.94 (0.65, 1.37)

Per SD increase

596/2191

1.26 (1.09, 1.45)

115/1153

1.24 (0.99, 1.56)

211/721

1.10 (0.92, 1.31)

267/305

1.18 (1.00, 1.40)

0.036

  1. AgeAccel, age acceleration; CI, confidence interval; DNAm, DNA methylation; HR, hazard ratio; MRscore, mortality risk score
  2. Numbers printed in bold: statistically significantly different from 1 (P < 0.05)
  3. *Overall HR was adjusted for age, sex, batch effects, tumor stage and leukocyte composition (Houseman’s algorithm)
  4. #Stage-specific HR was adjusted for age, sex, batch effects and leukocyte composition (Houseman’s algorithm)